PH25350A - PHOSPHOROUS-CONTAINING HMG-CoA REDUCTASE INHIBITORS - Google Patents

PHOSPHOROUS-CONTAINING HMG-CoA REDUCTASE INHIBITORS

Info

Publication number
PH25350A
PH25350A PH36956A PH36956A PH25350A PH 25350 A PH25350 A PH 25350A PH 36956 A PH36956 A PH 36956A PH 36956 A PH36956 A PH 36956A PH 25350 A PH25350 A PH 25350A
Authority
PH
Philippines
Prior art keywords
phosphorous
coa reductase
reductase inhibitors
containing hmg
hmg
Prior art date
Application number
PH36956A
Inventor
Donald Steven Karanewsky
Cott Adams Biller
Eric Michael Gordon
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Priority to PH38672A priority Critical patent/PH26228A/en
Publication of PH25350A publication Critical patent/PH25350A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/36—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PH36956A 1987-05-22 1988-05-20 PHOSPHOROUS-CONTAINING HMG-CoA REDUCTASE INHIBITORS PH25350A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PH38672A PH26228A (en) 1987-05-22 1989-05-19 An intermediate for the preparation of phosphorous containing CoA reductase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5328187A 1987-05-22 1987-05-22
US10968087A 1987-10-19 1987-10-19

Publications (1)

Publication Number Publication Date
PH25350A true PH25350A (en) 1991-05-13

Family

ID=26731667

Family Applications (1)

Application Number Title Priority Date Filing Date
PH36956A PH25350A (en) 1987-05-22 1988-05-20 PHOSPHOROUS-CONTAINING HMG-CoA REDUCTASE INHIBITORS

Country Status (24)

Country Link
JP (1) JP2680347B2 (en)
KR (1) KR880013958A (en)
CN (1) CN88103091A (en)
AU (1) AU610591B2 (en)
BE (1) BE1004193A3 (en)
CH (1) CH676984A5 (en)
DE (1) DE3817375C2 (en)
DK (1) DK277488A (en)
ES (1) ES2009918A6 (en)
FI (1) FI89493C (en)
FR (1) FR2615508B1 (en)
GB (1) GB2205837B (en)
GR (1) GR1000959B (en)
HU (1) HU205125B (en)
IE (2) IE930324L (en)
IL (1) IL86464A (en)
IT (1) IT1217685B (en)
NL (1) NL8801330A (en)
NO (1) NO882218L (en)
NZ (1) NZ224733A (en)
PH (1) PH25350A (en)
PL (1) PL154877B1 (en)
PT (1) PT87539B (en)
SE (1) SE503210C2 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2205838B (en) * 1987-05-22 1991-12-11 Squibb & Sons Inc Phosphorus-containing hmg-coa reductase inhibitors
CA2007643A1 (en) * 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination
CA2042526A1 (en) * 1990-06-11 1991-12-12 Adeoye Y. Olukotun Method for preventing a second heart attack employing an hmg coa reductase inhibitor
US5202327A (en) * 1991-07-10 1993-04-13 E. R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors
GB9126144D0 (en) * 1991-12-10 1992-02-12 British Bio Technology Compounds
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
CA2344300A1 (en) 1998-09-17 2000-03-23 Jeffrey A. Robl Method for treating atherosclerosis employing an ap2 inhibitor and combination
JP2004536047A (en) 2001-04-11 2004-12-02 ブリストル−マイヤーズ　スクイブ　カンパニー Amino acid conjugates and methods of C-aryl glucosides for treating diabetes
PL377687A1 (en) 2001-10-18 2006-02-06 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
WO2004037181A2 (en) 2002-10-23 2004-05-06 Bristol-Myers Squibb Company Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
AU2005221656B2 (en) 2004-03-05 2011-06-23 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
AR051446A1 (en) 2004-09-23 2007-01-17 Bristol Myers Squibb Co C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS (SGLT2)
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
WO2006076597A1 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7488725B2 (en) 2005-10-31 2009-02-10 Bristol-Myers Squibb Co. Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
EP2089355A2 (en) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
PE20090696A1 (en) 2007-04-20 2009-06-20 Bristol Myers Squibb Co CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM
EP2581081A3 (en) 2007-06-01 2013-07-31 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
JP2010534722A (en) 2007-07-27 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー Novel glucokinase activator and method of use thereof
CN101801954B (en) 2007-09-20 2013-10-09 Irm责任有限公司 Compounds and compositions as modulators of GPR119 activity
PE20091928A1 (en) 2008-05-29 2009-12-31 Bristol Myers Squibb Co HAVE HYDROXYSUSTITUTED PYRIMIDINES AS NON-BASIC MELANIN-CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
CA2756786A1 (en) 2009-03-27 2010-09-30 Bristol-Myers Squibb Company Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
CA2774573A1 (en) 2009-10-09 2011-04-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
RU2564901C2 (en) 2009-11-13 2015-10-10 Бристол-Майерс Сквибб Кампани Compositions of metformin with reduced weight
CA2780939C (en) 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Bilayer tablet formulations
RS57926B1 (en) 2009-11-13 2019-01-31 Astrazeneca Ab Immediate release tablet formulations
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011130459A1 (en) 2010-04-14 2011-10-20 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
MX342120B (en) 2010-07-09 2016-09-14 William Owen Wilkison Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin.
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
TWI631963B (en) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
KR102165224B1 (en) 2012-11-20 2020-10-13 렉시컨 파마슈티컬스 인코퍼레이티드 Inhibitors of sodium glucose cotransporter 1
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN104610262B (en) * 2013-11-01 2017-06-06 上海医药工业研究院 Biphenyl compound, intermediate, preparation method, pharmaceutical composition and its application
TW201702271A (en) 2015-04-30 2017-01-16 哈佛大學校長及研究員協會 Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders
CA3105626A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
AU2019346497A1 (en) 2018-09-26 2021-04-08 Lexicon Pharmaceuticals, Inc. Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA828650B (en) * 1981-12-01 1983-09-28 Hunt Chem Corp Philip A Herbicidal compositions and method using phosphonalkanoic acids, esters and salts thereof
FR2596393B1 (en) * 1986-04-01 1988-06-03 Sanofi Sa HYDROXY-3 DIHYDROXYOXOPHOSPHORIO-4 BUTANOIC ACID DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM
GB2205838B (en) * 1987-05-22 1991-12-11 Squibb & Sons Inc Phosphorus-containing hmg-coa reductase inhibitors

Also Published As

Publication number Publication date
CN88103091A (en) 1988-12-21
GR880100331A (en) 1989-02-23
FI89493B (en) 1993-06-30
PT87539B (en) 1992-09-30
IL86464A (en) 1993-06-10
FI89493C (en) 1993-10-11
PL272597A1 (en) 1989-03-06
HU205125B (en) 1992-03-30
IT8820682A0 (en) 1988-05-20
GB2205837A (en) 1988-12-21
IE881543L (en) 1988-11-22
AU1650888A (en) 1988-11-24
NZ224733A (en) 1990-12-21
HUT49358A (en) 1989-09-28
FR2615508A1 (en) 1988-11-25
FR2615508B1 (en) 1994-11-25
DE3817375A1 (en) 1988-12-08
DE3817375C2 (en) 1997-04-30
NO882218D0 (en) 1988-05-20
DK277488A (en) 1988-11-23
BE1004193A3 (en) 1992-10-13
IE63760B1 (en) 1995-06-14
PL154877B1 (en) 1991-09-30
IE930324L (en) 1988-11-22
ES2009918A6 (en) 1989-10-16
SE503210C2 (en) 1996-04-22
SE8801903D0 (en) 1988-05-20
NL8801330A (en) 1988-12-16
AU610591B2 (en) 1991-05-23
JPS6456689A (en) 1989-03-03
GB2205837B (en) 1991-11-20
FI882384A0 (en) 1988-05-20
GB8811929D0 (en) 1988-06-22
JP2680347B2 (en) 1997-11-19
IT1217685B (en) 1990-03-30
DK277488D0 (en) 1988-05-20
KR880013958A (en) 1988-12-22
SE8801903L (en) 1988-11-23
NO882218L (en) 1988-11-23
PT87539A (en) 1989-05-31
FI882384A (en) 1988-11-23
IL86464A0 (en) 1988-11-15
GR1000959B (en) 1993-03-16
CH676984A5 (en) 1991-03-28

Similar Documents

Publication Publication Date Title
PH25350A (en) PHOSPHOROUS-CONTAINING HMG-CoA REDUCTASE INHIBITORS
JPS6426535A (en) Novel hmg-coa reductase inhibitor
ZA865779B (en) Novel hmg-coa reductase inhibitors
EP0251625A3 (en) Novel hmg-coa reductase inhibitors
AU3313589A (en) 17beta-n-monosubstituted carbamoyl or 17beta-acyl-4-aza- 5alpha-androst-1-en-3-ones as 5alpha reductase inhibitors
AU1025588A (en) Novel peptidase inhibitors
EP0403487A4 (en) Novel hmg-coa reductase inhibitors
GB2205838B (en) Phosphorus-containing hmg-coa reductase inhibitors
AU3192289A (en) Nucleosidetype compounds which are phosphodiesterase inhibitors
ZA886468B (en) Novel hmg-coa reductase inhibitors
EP0323866A3 (en) Novel hmg-coa reductase inhibitors
JPS6463595A (en) Ribonucleotide reductase inhibitor
EP0415488A3 (en) 7-substituted hmg-coa reductase inhibitors
EP0306263A3 (en) Novel hmg-coa reductase inhibitors
EP0320052A3 (en) Intermediates and processes for 6-carboxy hmg-coa reductase inhibitors
ZA874487B (en) Novel hmg-coa reductase inhibitors
EP0468974A4 (en) Novel hmg-coa reductase inhibitors
IE871654L (en) Novel hmg-coa reductase inhibitors
GB9303051D0 (en) 17b-nmonosubstituted carbamoyl-11-oxo-4-aza-5-a-androst-en-3-one testosterone-5-alpha reductase inhibitors
IE861739L (en) Hmg-coa reductase inhibitors
ZA894895B (en) 5-oxygenated hmg-coa reductase inhibitors
IE822652L (en) HMG-CoA REDUCTASE INHIBITORS
IE882652L (en) NOVEL HMG-CoA REDUCTASE INHIBITORS
IE851368L (en) Preparing hmg-coa reductase inhibitors
ZA883620B (en) Phosphorus-containing hmg-coa reductase inhibitors,new intermediates and methods